GSK at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
GSK brings 20 presentations to IDWeek 2026 in Washington, and exhibits at Booth 1105, 1117, BS 2. Its program centres on oral tebipenem for complicated urinary tract infections and on the burden of vaccine-preventable diseases in adults, including RSV, flu, shingles and COVID. It also brings a natural language processing model that identifies when providers recommend adult immunizations.
| Organization | IDWeek 2026 Attendance |
|---|---|
GSK Philadelphia, PA | |
Biopharma company that prevents and treats disease with vaccines and with specialty and general medicines. | Booth Exhibiting at Booth 1105, 1117, BS 2 Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Industry Thu Oct 22 12:15pm–1:00pm Focusing on Complicated UTI: An Oral Option for Appropriate Patients Antimicrobials, resistance and stewardship Poster Thu Oct 22 12:15pm–1:30pm Human Simulated Dosing Regimens of Tebipenem Were Effective in a Rat Pyelonephritis Model against 16 Enterobacterales Poster Thu Oct 22 12:15pm–1:30pm Pharmacokinetic-Pharmacodynamic and Exposure-Response Assessment of Oral Tebipenem in Patients with Complicated Urinary Tract Infections Including Acute Pyelonephritis Poster Thu Oct 22 12:15pm–1:30pm Refined Pharmacokinetic/Pharmacodynamic (PK/PD) Targets to Support Oral Tebipenem (TBP) Treatment for Complicated Urinary Tract Infections (cUTI) Talk Thu Oct 22 2:30pm–2:45pm Estimating the Burden of Influenza in the Absence of Vaccination in the US Respiratory infections and COVID-19Vaccines Talk Thu Oct 22 3:45pm–4:00pm Talk Thu Oct 22 3:51pm–4:03pm Adjuvanted RSVPreF3 vaccine effectiveness against RSV-related hospitalization among US adults aged ≥60 years: Results from the CLEAR-VE RSV study over two RSV seasons VaccinesRespiratory infections and COVID-19 Industry Fri Oct 23 10:30am–10:50am Targeting HBsAg loss in HIV/HBV Co-Infection HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Industry Fri Oct 23 11:15am–12:00pm How PO Can You Go? IV to Oral Transition of Antimicrobials for Complicated UTIs Antimicrobials, resistance and stewardship Industry Fri Oct 23 12:15pm–1:00pm Hepatitis B Continuum of Care: Closing Gaps in Prevention to Treatment HIV, sexually transmitted infections and viral hepatitis Poster Sat Oct 24 12:15pm–1:30pm Boosting Uptake, Expanding Eligibility: Quantifying the Population and Equity Benefits of a Flu-Like COVID-19 Vaccination Strategy, a UK Example Poster Sat Oct 24 12:15pm–1:30pm Economic and Humanistic Burden of COVID‑19 in the US: Targeted Evidence Synthesis from the Post-Pandemic Era Poster Sat Oct 24 12:15pm–1:30pm Exploring Respiratory Syncytial Virus Vaccination Conversations Between Primary Care Providers and Their Adult Patients in the United States Poster Sat Oct 24 12:15pm–1:30pm Impact of Antibiotic Treatment Duration on Treatment-Related Adverse Events in Female Patients with Uncomplicated Urinary Tract Infections in the United States Poster Sat Oct 24 12:15pm–1:30pm Modeled Public Health Impact of Infant Meningococcal Serogroup B Vaccination Across United States Insurance Populations Poster Sat Oct 24 12:15pm–1:30pm Patient Reported Pain, Quality of Life, and Productivity Burden Following Herpes Zoster among United States Adults Aged 50–64 Years Poster Sat Oct 24 12:15pm–1:30pm Real-World Effectiveness of Ibrexafungerp in Patients with Vulvovaginal Candidiasis Poster Sat Oct 24 12:15pm–1:30pm Serotype-Specific Immune Response Elicited by Pneumococcal Conjugate Vaccines: a Systematic Literature Review Poster Sat Oct 24 12:15pm–1:30pm Variability in RSV Vaccination Uptake Across US Health Care Organizations and Across Primary Care Providers within US Health Care Organizations Poster Sat Oct 24 12:15pm–1:30pm hMPV Burden of Disease among Older Adults in High-Income Countries: a Systematic Literature Review |
Instantly find 20 buyers from GSK
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction